Alan was last valued at $5.5B (post-money). It comes from the $546M Series funding (June 2026) of Jun 2026. The company is private, so there is no listed share price.
1 valuation. The latest, $5.5B post-money, was set by the Series funding (June 2026) in Jun 2026.
A private valuation is the price agreed in one transaction. The Alan valuation of $5.5B is a post-money figure from the Series funding (June 2026) dated 25 Jun 2026 — the whole company measured after the $546M raised in that round was already inside it. Subtract the round and the pre-money view of the same deal is $5B .
The valuation holds until the next priced round or secondary sale. A private company founded in 2016 with roughly 790 people has no daily price and no order book between rounds.
The routes section explains what is realistically available for a company at this stage.
No. Alan is a private company; its shares do not trade on a public exchange.
The last valuation is $5.5B (post-money, Jun 2026).
Lead investors for each round are in the funding timeline.
The closest health insurance / insurtech peers are on the competitors page.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
